To explore the impact of CD40L or AID-deficiency on BCR usage in CLL, we performed IghV and IglV sequence analyses in selected CLL samples with high tumor load (>95% IgMb+CD5+CD43+CD19+ CLL-like cells) (Supplementary Table 1). This evidence concerns the gene CD19 and neoplasm.